乌苯美司联合TAC方案治疗三阴性乳腺癌临床研究

Clinical Study on Ubenimex Combined with TAC Regimen in the Treatment of Triple-Negative Breast Cancer

目的观察乌苯美司联合TAC方案治疗三阴性乳腺癌(TNBC)的临床疗效。方法选取医院2015年1月至2017年6月收治的TNBC患者168例,采用随机数字表法分为研究组与对照组,各84例。两组患者均给予TAC方案治疗,研究组患者加服乌苯美司片,两组均以21 d为1个疗程,治疗4个疗程。结果研究组总有效率为94.05%,明显高于对照组的73.81%(P<0.05);治疗后,两组患者各项生活质量评分均明显高于治疗前,且研究组明显高于对照组(P<0.05);治疗后,两组患者的CD3+,CD4+,CD4+/CD8+和自然杀伤(NK)细胞水平均较治疗前明显升高,CD8+水平较治疗前明显降低,且研究组均明显优于对照组(P<0.05);两组毒副作用发生率相当(P>0.05)。结论乌苯美司联合TAC方案治疗TNBC疗效较好,可有效改善患者的临床症状和生活质量,提高免疫功能。

Objective To observe the clinical efficacy of ubenimex combined with TAC regimen in the treatment of triple-negative breast cancer(TNBC).Methods Totally 168 patients with TNBC admitted to our Hospital from January 2015 to June 2017 were selected and divided into the study group and the control group according to the random number table method,84 cases in each group.The patients in the two groups were treated with TAC regimen,on this basis,the patients in the study group were treated with Ubenimex Tablets.Both groups were treated for 4 courses with 21 d as a course.Results The total effective rate of the study group was 94.05%,which was higher than 73.81%of the control group(P<0.05).After treatment,the score of life quality in the two groups was higher than that before treatment,and that in the study group was higher than that in the control group(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+and NK cells in the two groups were higher than those before treatment,while the level of CD8+in the two groups was lower than that before treatment,and those in the study group were better than those in the control group(P<0.05).There was no significant difference in the incidence of side effects between the two groups(P>0.05).Conclusion Ubenimex combined with TAC regimen in the treatment of patients with TNBC can effectively improve the clinical symptoms,quality of life and the immune function.